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An increasing number of patients with tetralogy of Fallot require repeat surgical interven-
tion for pulmonary valve replacement secondary to pulmonary regurgitation. Catheter-
based interventions have emerged as an attractive alternative to surgery in this patient
population but it is limited by patient size or the anatomy of the right ventricular outflow
tract. Hybrid approaches involving both cardiac interventionists and surgeons are being
developed to overcome these limitations. The purpose of this review is to highlight the
recent advances in the hybrid field of pulmonary valve replacement, summarizing the
advantages and disadvantages of the “traditional” surgical and the new catheter-based
techniques and discuss the direction future research should take to determine the optimal
management for individual patients.
Keywords: pulmonary valve insufficiency, tetralogy of fallot, hybrid intervention, congenital heart disease, cardiac
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Introduction
In the current era, ~90% of infants born with tetralogy of Fallot (ToF) are expected to live
beyond 40 years of age making it the fastest growing population among patients with congenital
heart disease (1). One of the most common late consequences after repair of ToF is pulmonary
valve regurgitation (PVR). Significant PVR results in progressive dilatation and dysfunction of
the right ventricle, decrease in exercise tolerance, arrhythmias, heart failure, and increased risk
of sudden death (2). The number of operations for PVR has been increasing over the past
decade (3).
The conventional approach of dealing with this problem is to perform pulmonary valve
replacement using cardiopulmonary bypass (CPB) and cardioplegic arrest (2). However, this
approach is associated not only with long operative times but also side effects related to the use
of CPB.
Development of percutaneous approaches to valve disease is one of the most exciting areas of
clinical innovation and cardiovascular medicine. The main development has been that of tran-
scatheter pulmonary valve replacement for the rehabilitation of conduits between the right ventricle
and pulmonary artery in patients after surgery for ToF. Percutaneous approaches avoid the need
for CPB; however, there are limitations to the size of the valve that can be implanted and there is
no opportunity to repair additional defects such as pulmonary artery dilatation, which is frequently
associated with severe PVR.
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The advent of the hybrid surgical options for treating cardiac
disease has integrated the techniques of interventional cardiology
with the techniques of cardiac surgery to provide a formof therapy
that combines the respective strengths of both fields.
In this focused review, we present and compare recent advances
in traditional surgery, and hybrid procedures to replace the pul-
monary valve in patients with ToF presenting with severe PVR
and dilated right ventricular outlet tract (RVOT). We summarize
the advantages and disadvantages of each approach and discuss
the direction future research should take to determine the optimal
management for individual patients.
Surgical Outcomes
The surgical options for PVR are still regarded by many car-
diologists and cardiac surgeons the “gold standard” for young
adult patients with pulmonary regurgitation after their initial
ToF repair. There are several recent studies describing long-
term outcomes for surgical pulmonary valve replacement (SPVR).
McKenzie et al. (4) conducted a retrospective analysis of outcomes
in patients who underwent SPVR to provide a benchmark for
comparison with the new emerging transcatheter techniques.
Over a 15-year period, 247 patients with obstructive right
heart lesions who developed pulmonary valve dysfunction were
included in the study. More than 100 (42%) patients had a history
of repaired ToF, and in 50% of the cases, regurgitation was the
indication for SPVR. They showed average hospital stay of 5 days,
99% survival, and 94% freedom from reintervention at 5 years.
Sabate Rotes et al. (5) looked specifically at SPVR in patients
with repaired ToF who develop PR, in a retrospective analysis of
278 cases over a 40-year period. They showed an early survival
of 98.6% and 80% at 15 years, with a 97% freedom from pul-
monary valve reintervention at 5 years. Patients who had under-
gone ToF repair at an older age had increased mortality, but also
an increased protection against pulmonary valve reintervention.
A further large retrospective study of patients with a history of
repaired ToF undergoing SPVRwas undertaken by Babu-Narayan
et al. (2). Over a 17-year period, 220 cases of SPVR were included.
The group showed similar results to those of the studies previously
mentioned with 97.7% 30-day survival, 96% survival at 3 years,
and 96% freedom from reintervention at 10 years. Survival in the
later era (2005–2010; n= 156) was significantly better compared
with survival in the earlier era (1993–2004; n= 65; 99% vs 94% at
1 year and 98% vs 92% at 3 years, respectively; p= 0.019).
Table 1 (2, 4, 6–10) shows the results of themost recent surgical
series with comparable study populations. It is quite clear from all
these studies that there are large bodies of evidence to suggest that
SPVR is a safe and effective technique in patients who develop
PVR after repair of ToF. Patients therefore should be educated
that SPVR does not confer higher procedural risk and has low in-
hospital and midterm follow-up mortality and re-operation rates.
Nevertheless, there is still an operative mortality risk that varies
from 1% to almost 3%, andmorbidity associated to the use of CPB
and myocardial cardioplegic arrest. This will inevitably trigger a
widescale inflammatory response with negative effects on several
organ functions. Furthermore, there is a much higher chance
of requiring blood product transfusion when CPB is used for
TABLE 1 | Outcomes comparison for recent published surgical pulmonary
valve replacement series.
First author Year Sample
(n)
30-day
mortality
5-year
mortality
5-year redo-
intervention
Babu-Narayan
et al. (2)
2014 220 2% 4% 2%
McKenzie et al. (4) 2014 148 0 N/A 6%
Batlivala et al. (6) 2012 254 1.2% 1.9% 3%
Chen et al. (7) 2012 227 0 3% 6%
Lee et al. (8) 2012 170 1.2% 1.2% 2.9%
Jang et al. (9) 2012 131 0 0 3.5%
Zubairi et al. (10) 2011 169 0.6% N/A 7%
corrective cardiac surgery. Another aspect to consider is that these
reports all present the medium-term outcomes for homograft or
allograft valves, which are chosen to avoid anti-coagulation in a
cohort of young patients. While they ensure freedom from anti-
coagulation, their durability is limited and over time the majority
will degenerate and require re-operation. There have been several
recent publications looking at using mechanical valves for PVR
to try and reduce the rate of reintervention (11–15). One of
the most serious complications with these valves is thrombosis
althoughmany thrombosed valves can be successfully treatedwith
fibrinolytic therapy without needing valve extraction. The risk of
bleeding events was low in these series. Mechanical valves may
offer a longer term solution in a select group of patients who are
compliant with anti-coagulation therapy or have already received
a mechanical prosthesis on the tricuspid or the left side valves.
Overall, these outcomes provide a useful benchmark for treatment
strategy comparisons.
Percutaneous PVR
In 2000, pioneering work was carried out by Bonhoeffer et al.
demonstrating the feasibility of percutaneous PVR (PPVR) in
a 12–year-old patient (16). This minimally invasive approach
offered the benefit of reducing the need for repeated open-valve
replacement and potentially avoiding it all together.
Many groups have continued to develop the technique and
shown its potential as a valuable alternative to SPVR. In the first
extended human study of PPVR, Khambadkone et al. (17) showed
successful valve deployment in 58 out of the 59 patients, 0%
mortality at 10months, but device complications in 14 patients
(25%). However, these results have improved over time and Lurz
et al. showed a reduction in complications to 2.5% (18).
Furthermore, the US Melody Valve Trial (19), which included
129 patients with dysfunctional RV-PA conduits was associated
with 94% freedom from PV intervention at 1 year. Eicken et al.
(20) produced a report lending further evidence to the feasibility
of PPVR. This two-center study took 102 cases of PPVR as a treat-
ment for pulmonary regurgitation in patients with dysfunctional
RV to PA conduits. They were able to show a significant reduction
in pulmonary regurgitation in all patients with a range of hemody-
namic changes pointing to improved RV function postprocedure.
However, they also showed stent fracture in 5% of the patients (a
reduction from previously reported stent fractures rates of over
20%) and 8% of patients require repeat dilatation of the valve so
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highlighting the room for improvement with the technique. In an
extension of their US Melody Valve Trial, McElhinney et al. (21)
carried out some further observations to better understand the
risk factors for these common complications in PPVR. In a mul-
ticenter study, they showed that patients with severely obstructed
RVOT conduits were more likely to suffer stent fracture, and the
benefit of pre-stenting in preventing stent fracture and reducing
the incidence of reintervention.
Despite the rapid progress of PPVR, long-term outcomes as
described for SPVR have not yet been produced. Recently, Dil-
ber et al. (22) conducted a single-center retrospective study of
patients with RVOT dysfunction who had undergone either SPVR
or PPVR based on the indications for each of these procedures.
The authors concluded that patients with RVOT dysfunction can
be treated effectively using a complementary treatment concept,
including SPVR and PPVR. This approach is dependent on deci-
sions made by a team of surgeons and interventionists regarding
which valve replacement techniques are appropriate for the patient
in question. The PPVR patients were shown to benefit from
shorter hospital stay, less complications postprocedure, and were
more likely to return to usual daily activities sooner following
discharge.
However, with the percutaneous technique, there is a limitation
of the size of prosthesis, which can be inserted, currently up
to 22mm with the Melody valve (Medtronic Inc., Minneapolis,
MN, USA) and up to 29mm diameter with the Sapien tran-
scatheter heart valve (Edwards Life-sciences LLC, Irvine, CA,
USA) although off label uses of both have extended slightly
beyond these measurement limitations (23–25). Therefore, in
Dilber’s centre, which uses Melody valves (Medtronic Inc., Min-
neapolis, MN, USA), patients needed to have RVOT diameter
<22mm. Those patients with large RVOTs who often presented
with pulmonary regurgitation automatically fell into the surgical
group.
Moreover, the technique does not offer the opportunity of
treating additional defects that are frequently associated with
severe PR, such as pulmonary artery dilatation, and it cannot
be used in the dilated native RVOT, which constitutes over 85%
of patients with ToF requiring pulmonary valve replacement,
because it requires a relative constriction for adequate fixation.
This highlights the main limitation of PPVR: it is not currently
suitable for use in patients with native and large RVOTs, although
some valve designs are evolving for use in the native RVOT they
are unlikely to be widely clinically available anytime soon (26,
27). Boudjemline et al. (28) demonstrated an interesting technique
in patients with large patched RVOTs to assess the feasibility
of this technique as a treatment for pulmonary regurgitation in
this patient group. The technique involved preparation of the
large RVOTs with telescoping of multiple stents from the branch
pulmonary arteries to act as a landing zone for concomitant
transcatheter PV insertion. They showed 100% successful valve
deployment, with no cases of stent fracture or migration. How-
ever, only 12 patients were included in this study, so a larger study
with longer term follow-up would be needed to draw any firm
conclusions.
As longer term outcomes are reported, there are also con-
cerning reports of a higher incidence of bacterial endocarditis in
PPVR when compared to the open approach. Buber et al. (29)
reported a 9.5% incidence of bloodstream infections and 2.7%
of patients had prothestic endocarditis after a median follow-up
of 19months. Reviewing results from the Melody Valve Trial,
which included 311 patients with a median of 2.5 years follow-up,
McElhinney et al. (30) found an annualized rate of transcatheter
valve endocarditis of 0.88% per patient-year. When valve related
endocarditis occurs, the majority of patients requires surgical
prosthesis replacement (31). A recent comparison of the Melody
valve with surgical implants demonstrated an incidence ofMelody
endocarditis of 7.5% during a median follow-up of 2 years (32).
Homograft endocarditis rate was 2.4%, and endocarditis with
the Contegra conduit was 20.4%. Survival free of endocarditis
by Kaplan–Meier for homografts was 98.7% at 5 years; however,
for the Melody valve, it was 84.9% and this is probably the most
concerning longer term issue surrounding this valve.
Hybrid PVR
Transcatheter pulmonary valve implantation has the potential to
become the standard procedure in the treatment of dysfunctional
conduits. Nevertheless, the majority of ToF patients (85%)
presents with native outflow tracts and free pulmonary regurgi-
tation and represents a big challenge for these new technologies.
Over the last decade, there has been a significant evolution of car-
diac surgery toward less invasive strategies, and at the same time,
an expansion of interventional cardiology toward more com-
plex procedures involving structural, congenital, and large vessel
intervention. The development of hybrid cardiac catheterization
laboratories has allowed a strong collaboration between surgeons
and interventionalistsmainly in the field of valve replacement, one
of the fastest growing procedures in the United States.
At the Bristol Heart Institute and at the Rush University Med-
ical Center, we have been pioneering new hybrid techniques
for pulmonary valve replacement in ToF patients and we have
recently published our first experience (33) with a newly devel-
oped tissue valve mounted on a self-expanding stent, the No-
React Injectable BioPulmonic (BioIntegral Surgical Inc., Toronto,
Canada) (Figure 1A). This technique requires only minimal
mobilization of the heart and great vessels and thus reduces both
the operative time and the risks associated with extensive dis-
section, such as bleeding and injury to the heart, great vessels,
and adjacent structures (e.g., phrenic nerves). Furthermore, the
valve is implanted without using CPB and cardioplegic arrest,
thereby avoiding its adverse side effects. The Injectable BioPul-
monic prosthesis currently is available in sizes up to a diameter
of 31mm.
This strategy requires a full median sternotomy, plication of
the pulmonary artery and a stab incision on the anterior sur-
face of the proximal RVOT just proximal to the infundibu-
lum/infundibular patch, avoiding calcified tissue. A valve 2mm
in diameter larger than the maximum size measured is gen-
tly compressed into the introducer and slid into the provided
trocar. The injector is then slid into the RVOT and advanced
to the main PA (Figures 1B,C). The trocar delivery system is
then withdrawn and the purse-string sutures controlled. Trans-
esophageal and epicardial echocardiogram are used to assess the
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FIGURE 1 | (A) The biopulmonic valve inserted into the delivery system;
(B), the RVOT has been plicated and a purse string passed in the anterior wall
of the right ventricle, just below the RVOT; the introducer is then positioned on
top of the RVOT and the length of the valve (arrows) is then compared with the
length of the RVOT before the injection; (C) the biopulmonic valve within the
delivery system is inserted into the RVOT through an incision below the previous
transannular patch, and after delivery, the valve is stitched from the outside
(arrow) to prevent any movement and possible migration.
valve position throughout the process of deployment. The valve
can then secured with external Prolene sutures placed in the
proximal anddistal rimof the valve. These pilot data on 10 patients
comparing the off-pump hybrid pulmonary valve replacement
(HPVR) with the on-pump conventional SPVR showed that
off-pump HPVR was associated with a significant reduction in
operating time (165.7 43.3 range 110–240min, vs 298.6 57.4
range 221–375min, p< 0.001) blood loss (83.3 28.6mL vs
527.1 485.3mL, p< 0.05), blood products requirement (0 units
vs 3.6 3.9 units, p< 0.05) and higher postoperative hemoglobin
levels (13.4 1.7 g/dL vs 9.8 1.7 g/dL, p< 0.001) compared with
on-pump SPVR. No patient had paravalvular leak or more than
mild pulmonary regurgitation at an early follow-up, indicating
that off-pump HPVR is a safe and effective surgical strategy and
a possible beneficial alternative to the traditional on-pump PVR.
A possible disadvantage of this technique is the fact that it still
requires a significant incision into the anterior wall of the right
ventricle, with possible early complications such as muscle tear
and significant bleeding and long-term localized wall motion
abnormalities and arrhythmias, even though we have not seen
this complication in our patient population. Furthermore, there is
potential risk of incorrect positioning of the valve eithermigrating
toward the branch pulmonary arteries or sitting too proximally in
the RVOT.
Dittrich et al. (34) reported a case of HPVR in a patient with
enlarged RVOT after ToF repair. The technique employed was
similar to ours, with the exception that access to the PA was via
the third intercostal space and not a median sternotomy, and the
valve was inserted through the pulmonary artery and not the
right ventricle. They concluded that this technique was better
than percutaneous transcatheter PVR in terms of its suitability for
patients with enlarged RVOTs.
For small children with ToF and significant PR at the Rush
University Medical Center, we have adopted a different hybrid
technique for pulmonary valve implantation (35). The approach
involved a subxyphoid incision and a delivery sheath to implant
the valve, inserted into the right ventricle (Figure 2). This strategy
has the advantage of avoiding a sternotomy (only the lower carti-
laginous part of the sternum is divided leaving the main body of
the bone intact) but still requires an opening of the right ventricle
for the insertion of the valve (Figure 2).
For the majority of patients with native RVOT and free PR
post ToF repair, we have routinely adopted a hybrid strategy
of pulmonary artery plication through a limited sternotomy or
thoracotomy and transvenous insertion of a Melody pulmonary
valve (36). The strategy is based on a preoperative angiogram for
the assessment and measurement of the RVOT (Figure 3A). The
pulmonary artery is then plicated in order to reduce its diameter
by ~30% (Figure 3A). This creates a tubular structure that acts
as a landing zone for the Melody valve (Figure 3B). A similar
technique has been recently published as a case report by Travelli
et al. (37), but instead of using a longitudinal plication, they
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FIGURE 2 | (A, B) Subxyphoid incision and a delivery sheath to implant the valve, inserted into the right ventricle; (C) delivery of the melody valve and controlled
angiogram.
FIGURE 3 | (A) Assessment and measurement of the RVOT with angiography before and after extensive plication of the previous transannular patch;
(B) transcatheter insertion of the melody valve into the RVOT.
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applied a band around the main pulmonary artery. Postoperative
angiography and intracardiac echocardiography are used to eval-
uate the efficacy of the treatment (Figure 3B). Our pilot data on
the first five young adults who have received this technique is very
encouraging, demonstrating an excellent quality of postoperative
recovery and early discharge. Extensive calcification of the pre-
existing RVOTpatchmay impede upon the ability to perform ade-
quate placation, and this should be assessed with a pre-procedural
postero-anterior and lateral chest X-ray. Use of a compliant sizing
balloon to guide the extent of plication and to ensure there is
an adequate-diameter landing zone following plication may help.
Ensuring adequate stability of the pre-stent is a key, and a sur-
gical suture to anchor the stent to the RVOT may be employed.
Another limitation for the hybrid approach is the inability to
perform associated surgical procedures such as right ventricular
remodeling and RVOT ablation, even though the RVOT plication
does significantly decrease the RVOT size. The presence of branch
pulmonary artery stenosis can still be approached hybridly by
stenting the vessels before the surgical RVOT plication and valve
delivery. Nevertheless, branch PA narrowing requiring stenting
may complicate the RVOT interventions particularly when there
is left-sided pulmonary artery narrowing (usually provides the
best site for the guidewire for pulmonary valve implantation). The
carrot of theMelody valvemay not traverse the stented vessel well,
and this may impact upon stability of either the left pulmonary
artery stent or the RVOT stent during valve implantation.
We have elected to deliver the valve from the groin rather
than through the ventricle in an attempt to minimize myocardial
scarring known to be a risk factor for ventricular tachyarrhythmia
in this group of patients. Indeed, it is our attention to these
marginal potential benefits that will define our successes with
congenital heart disease patients over the next 30 years as mor-
tality no longer becomes an acceptable outcome variable to define
success. It is also possible that valve longevity in the absence of
significant RVOT narrowing, shown to be a risk factor for valve
stent degeneration (21)may be greater with this approach and cer-
tainly subjective assessment of external compressive forces on the
valve stent in our early experience is encouraging. A les- invasive
strategy for pulmonary artery plication using a thoracoscopic or
a small thoracotomy approach should be considered in the future
for further decreasing the invasiveness of this innovative hybrid
technique, even though it is well proven that previous sternotomy
does not increase the risk in congenital cardiac surgery (38). Some
may question the validity of such an approach as at present it still
requires a sternotomy. Indeed, the ideal solution is a transcatheter
valve systemdesigned specifically for the native outflow. Although
two such systems are being evaluated in clinical trials, it may be
many years before this technology is available, and therefore, we
feel we should continue to push the boundaries for these patients,
providing the least invasive options with optimal longer term
outcomes including risk of arrhythmia and sudden cardiac death
from myocardial scarring.
In our overall series of more than 20 patients who underwent
an HPVR, at short-term follow-up (<4 years), all patients are
alive and asymptomatic, with no signs of valve degeneration or
infection. Longer follow-up, bigger sample size, and controlled
randomized trials are required to clearly demonstrate the efficacy
of the HPVR strategy compared with the SPVR, which is still
considered the gold-standard procedure for patients with ToF
and PVR.
Conclusion
With the advance of less invasive technologies and new imag-
ing techniques, a dedicated collaboration between cardiotho-
racic surgeons and interventionalists becomes mandatory for the
treatment of congenital heart disease. Hybrid PVR is gaining
increasing recognition as a less invasive alternative to SPVR, to
minimize procedure time, risks and complications and greatly
improve the quality of recovery for this population. These ben-
efits to patients are expected to translate into benefits for the
Health System as well, with fewer resources needed during the
operation and for postoperative care. However, high-quality evi-
dence, which can only be obtained by carrying out a randomized
controlled trial, is needed to estimate the effectiveness and cost-
effectiveness of the new technology of HPVR compared to the
standard SPVR and to inform decisions about adoption of this
interesting approach to RVOTdysfunction by surgeons and health
care policy makers.
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